Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CKPT Checkpoint Therapeutics	$1.51 -5.9%	$1.96	$1.30 ▼ $3.62	$53.71M	0.99	542,866 shs	561,627 shs
LUMO Lumos Pharma	$2.70 +3.1%	$2.86	$2.41 ▼ $4.55	$21.92M	0.65	20,647 shs	11,450 shs
OASM Oasmia Pharmaceutical AB (publ)	$0.02	$1.46	$0.94 ▼ $5.70	$1.50M	0.96	98,414 shs	N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CKPT Checkpoint Therapeutics	-4.19%	-12.57%	-13.51%	-13.04%	-48.22%
LUMO Lumos Pharma	+6.50%	-3.32%	-4.03%	-10.88%	-14.66%
OASM Oasmia Pharmaceutical AB (publ)	0.00%	0.00%	0.00%	0.00%	-60.00%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CKPT Checkpoint Therapeutics	3.1629 of 5 stars	3.5	1.0	0.0	4.2	2.3	0.8	0.0
LUMO Lumos Pharma	1.4495 of 5 stars	3.5	1.0	0.0	0.0	0.0	2.5	1.3
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CKPT Checkpoint Therapeutics	3.00	Buy	$22.60	1,401.66% Upside
LUMO Lumos Pharma	3.00	Buy	$18.00	566.67% Upside
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CKPT, OASM, and LUMO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/22/2024	CKPT Checkpoint Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$34.00
3/20/2024	LUMO Lumos Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CKPT Checkpoint Therapeutics	$100K	537.13	N/A	N/A	($0.47) per share	-3.20
LUMO Lumos Pharma	$2.05M	10.69	N/A	N/A	$3.45 per share	0.78
OASM Oasmia Pharmaceutical AB (publ)	$220K	6.82	N/A	N/A	$0.63 per share	0.03

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CKPT Checkpoint Therapeutics	-$51.85M	-$3.33	N/A	∞	N/A	-50,336.89%	N/A	-950.01%	5/20/2024 (Estimated)
LUMO Lumos Pharma	-$34.03M	-$4.19	N/A	N/A	N/A	-1,659.39%	-85.63%	-65.30%	5/1/2024 (Estimated)
OASM Oasmia Pharmaceutical AB (publ)	-$18.95M	N/A	0.00	∞	N/A	-8,633.64%	-43.94%	-28.92%	N/A

Latest CKPT, OASM, and LUMO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/22/2024	Q4 2023	CKPT Checkpoint Therapeutics	-$0.74	-$1.10	-$0.36	-$1.10	$0.09 million	$0.01 million
3/7/2024	Q4 2023	LUMO Lumos Pharma	-$1.18	-$1.17	+$0.01	-$1.17	$0.01 million	$0.83 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
LUMO Lumos Pharma	N/A	5.69	5.69
OASM Oasmia Pharmaceutical AB (publ)	N/A	0.80	0.73

Ownership

Institutional Ownership

Company	Institutional Ownership
CKPT Checkpoint Therapeutics	22.00%
LUMO Lumos Pharma	33.99%
OASM Oasmia Pharmaceutical AB (publ)	0.11%

Insider Ownership

Company	Insider Ownership
CKPT Checkpoint Therapeutics	2.10%
LUMO Lumos Pharma	23.70%
OASM Oasmia Pharmaceutical AB (publ)	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CKPT Checkpoint Therapeutics	23	35.69 million	34.94 million	Optionable
LUMO Lumos Pharma	33	8.12 million	6.19 million	Not Optionable
OASM Oasmia Pharmaceutical AB (publ)	57	74.97 million	N/A	Not Optionable

CKPT, OASM, and LUMO Headlines

Source	Headline
	Lipigon Pharmaceuticals AB LPGO morningstar.com - March 23 at 12:53 AM
	LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Resurs Holding AB (publ) (RESURS.ST) finance.yahoo.com - February 8 at 12:32 AM
	QuiaPEG Pharmaceuticals Holding AB QUIA morningstar.com - January 6 at 5:30 PM
	Newbury Pharmaceuticals AB (NEWBRY) investing.com - November 29 at 2:08 AM
	Dentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzyme bestmediainfo.com - September 26 at 1:06 AM
	Lipigon Pharmaceuticals AB (LPGO) investing.com - September 14 at 9:09 AM
	Speqta publ AB (SPEQT) investing.com - August 25 at 9:50 PM
	PRXXF Paradox Interactive AB (publ) seekingalpha.com - August 25 at 9:29 AM
	Notice of annual general meeting in Alzinova AB (publ) privataaffarer.se - April 25 at 8:37 AM
	Report from Annual General Meeting 2023 of PowerCell Sweden AB (publ) privataaffarer.se - April 21 at 8:26 PM
	Notice of Annual General Meeting 2023 in Enzymatica AB (publ) (2) europapress.es - April 2 at 9:53 AM
	OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M seekingalpha.com - February 26 at 11:56 PM
	US regulators clear way for more monkeypox vaccine shipments starherald.com - July 14 at 11:12 AM
	PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN) avanza.se - March 24 at 6:47 AM
	Oasmia expands R&D ability with planned laboratory upgrade privataaffarer.se - March 17 at 8:40 AM
	Orexo appoints Fredrik Järrsten as new CFO stockhouse.com - March 11 at 3:47 AM
	Notice of extra general meeting in Terranet AB finanznachrichten.de - November 29 at 10:24 AM
	Pet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth \| robust CAGR of 7.7% over the forecast period (2017 – 2025). medgadget.com - September 17 at 2:52 AM
	Veterinary Cancer Therapeutics Market Segmentation, Size Analysis, Key Players Forecast To 2027 openpr.com - July 28 at 7:04 PM
	Fancy Wood Industries PCL (FANCY) investing.com - July 22 at 7:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Checkpoint Therapeutics

NASDAQ:CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Lumos Pharma

NASDAQ:LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Oasmia Pharmaceutical AB (publ)

NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial